- Home
- ARGX
ARGX
argenx SE
as 05-09-2025 10:31am EST
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
| Founded: | 2008 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 40.4B | IPO Year: | 2017 |
| Target Price: | $699.56 | AVG Volume (30 days): | 395.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 15.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $352.77 - $678.21 | Next Earning Date: | 05-08-2025 |
| Revenue: | $2,643,062,000 | Revenue Growth: | 82.13% |
| Revenue Growth (this year): | 60.97% | Revenue Growth (next year): | 31.50% |
Latest argenx SE News
ARGX Breaking Stock News: Dive into ARGX Ticker-Specific Updates for Smart Investing
GuruFocus.com
8 hours ago
argenx SE (ARGX) Q1 2025 Earnings Call Highlights: Record Growth and Strategic Advances
MT Newswires
a day ago
Sector Update: Health Care Stocks Decline Pre-Bell Thursday
Investor's Business Daily
a day ago
Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble
MT Newswires
a day ago
Argenx Reports Q1 Earnings, Higher Operating Income; Shares Down Pre-Bell
GlobeNewswire
a day ago
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
Insider Monkey
2 days ago
argenx SE (ARGX): A Bull Case Theory
GlobeNewswire
3 days ago
argenx to Present at BofA Securities 2025 Health Care Conference
Insider Monkey
8 days ago
Is argenx SE (ARGX) the Most Profitable Growth Stock to Buy Now?
Compare ARGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARGX argenx SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.